Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Similar Posts
I held onto Intel too long, says MarketRebellion.com’s Jon Najarian
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email The ‘Halftime Report’ investment committee — Steve Weiss, Pete Najarian, Joe Terranova and Karen Firestone — discuss CITI’s bearish call on Intel and the company’s outlook. 02:19 Wed, Jun 8 20221:08 PM EDT
Shari Redstone launches formal auction of National Amusements: Report
CNBC’s Andrew Ross Sorkin reports on the latest news.
The best April Fools’ pranks of 2015
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Entertainment From Burger King’s Whopper scent to Honda’s selfie car, these companies are redefining funny this April Fools’. 01:13 Wed, Apr 1 20152:15 PM EDT Sophie Bearman
How beer benefits the US economy
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Beer is the most popular alcoholic drink in the U.S. But did you know the beer industry employs over 2 million Americans? 00:53 Tue, Apr 7 20154:00 PM EDT
Goldman downgrades key defense stocks to sell
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email CNBC’s Morgan Brennan joins ‘Power Lunch’ to report on Goldman Sachs’ sweeping downgrade of key stocks in the defense sector. 03:57 Fri, Jan 13 20232:43 PM EST
RapidRatings’ James Gellert: Boeing declines in financial health rating
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email The Exchange James Gellert, RapidRatings executive chair, joins ‘The Exchange’ to discuss the financial health of Boeing, shipping companies, and more. 03:24 2 hours ago
